CLEAR FORM

Prescription and Enrolment Form[1]

PrPEMAZYRE® has been issued conditional marketing authorization pending the results of studies to verify its clinical benefit. Patients should be advised of this conditional marketing authorization.

PEMAZYRE® (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.[1]

Please fax this form to **1-84-INCYTE-01** (1-844-629-8301) or email it to **support@incytesolutions.ca**.
For more information, call the Incyte Solutions™ Support Program at **1-84-INCYTE-00** (1-844-629-8300).

Pr Pemazyre pemigatinib tablets 13.5mg·9mg·4.5mg | Incyte Solutions™ SUPPORT PROGRAM

Patient information and consent

Last name _____ First name _____ Date of birth (DD/MM/YYYY) _____ Sex ☐ F ☐ M ☐ Other _____

Preferred language ☐ English ☐ French ☐ Other _____ Preferred phone # _____ Alternate phone # _____

Consent to leave voicemail ☐ Yes ☐ No Email _____ Preferred communication ☐ Phone ☐ Email ☐ SMS

By providing my mobile phone number and/or my email address, I agree to receive electronic messages using such coordinates from the Incyte Solutions™ Support Program. I understand that I can withdraw my consent in whole or in part at any time by informing the Program in writing.

By signing this form I agree to and have read and understood the above terms and the Patient Terms and Conditions on the reverse side.

Patient or legal representative signature _____ Date (DD/MM/YYYY) _____

If signed by legal representative, name of legal representative and relationship to the patient _____

Prescribing healthcare professional (HCP) information and authorization

Last name _____ First name _____

Specialty _____ City and province _____

Work phone _____ Fax _____

Email _____ Prefer communication by ☐ Phone ☐ Fax ☐ Email

Clinic primary contact/nurse email (if applicable) _____

Clinic stamp and/or additional information:

Diagnosis and previous treatment(s)[1]

Diagnosis: ☐ Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement

Confirmed genetic alteration:

☐ FGFR2 fusion or other rearrangement Please specify _____

Name of testing lab (e.g., for next generation sequencing [NGS]) (if available) _____

Additional information (if available):

Prior line(s) of therapy (select all that apply): ☐ First-line Please specify _____

☐ Second-line Please specify _____ ☐ Other Please specify _____ Year of diagnosis _____

Prescription information[1]

Dosage: oral tablet taken once daily (14-day supply)*

☐ PEMAZYRE® 13.5 mg ☐ PEMAZYRE® 9.0 mg ☐ PEMAZYRE® 4.5 mg

Refill information _____

Additional comments _____

This prescription represents the original of the prescription drug order. My signature acknowledges that the patient has been prescribed PEMAZYRE® for the treatment noted above. By signing this form, I have read and agree to the Prescribing HCP Terms and Conditions on the reverse side.

Prescribing HCP signature _____

Prescribing HCP License Number _____ Date (DD/MM/YYYY) _____

☐ Check here if prescribing HCP has obtained verbal consent from the patient to share their information with the Program for contact and enrolment purposes

Refer to the PEMAZYRE® Product Monograph for more information on the recommended dose and dose adjustments.

* Each cycle is 21 days long: PEMAZYRE® should be taken for 14 consecutive days followed by 7 days off therapy. Continue treatment until disease progression or unacceptable toxicity.

Please consult the Product Monograph at pdf.hres.ca/dpd_pm/00062968.PDF for important information relating to conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions, dosing, monitoring and laboratory tests, which have not been discussed in this piece. The Product Monograph is also available by calling 1-833-309-2759 or contacting medinfocanada@incyte.com.

Pr Pemazyre pemigatinib tablets 13.5mg·9mg·4.5mg

Patient Terms and Conditions

The Incyte Solutions™ Support Program is sponsored and offered by Incyte Biosciences Canada Corporation ("Incyte") in order to support patients who have been prescribed PEMAZYRE® (pemigatinib) (the "**Program**"). The Program is administered by Incyte and a third-party service provider retained by Incyte to administer the Program, along with their agents and affiliates (collectively, "**Program Administrators**"). Reference to "you", "your" or "I" in this document refers to you as the patient.

In order to enrol you in the Program, your healthcare professional has provided the Program with certain information about you, as outlined on the Prescription and Enrolment Form including your personal information (name, gender, date of birth, address, telephone number, email) and personal health information (medical and insurance information as it affects your therapy and prescription reimbursement) (collectively, your "**Information**").

The Program will collect, use, disclose and store your Information to provide you with the following services ("**Program Services**"):

- Nursing and/or pharmacists' support
- Assessment of eligibility to financial assistance
- Assistance in communicating with drug plan administrators, managers or insurance companies to aid in securing reimbursement coverage for your prescription
- Reporting on your insurance coverage to your prescribing healthcare professional (HCP)
- Regular communications on your therapy and support program offerings, where applicable
- Other services as offered from time to time.

Please note that enrolment in the Program may allow access to your Information and/or Program data by healthcare professionals involved in your treatment. By signing and submitting this form, you are consenting to the collection, use and disclosure of your Information by the Program Administrators for administration of the Program and the provision of Program Services and as required or permitted by law and in accordance with the Program's Privacy Policy, which can be obtained by contacting the Program. You also understand that the Program Administrators may contact you according to Information provided in Section 1 of the first page in connection with administration of the Program and provision of Program Services, and you agree to be contacted now and in the future by the Program Administrators including regarding the Program, your condition and/or your PEMAZYRE® (pemigatinib) prescription.

In addition, you authorize the Program to obtain further information from your prescribing HCP and health insurance company as deemed necessary to ensure the accuracy and completeness of your Information and to administer the Program, and that such further information may include personal information and/or personal health information.

Use and disclosure of your Information

The Program will keep the Information that you provide confidential and will use it only for the purposes of providing you with Program Services and information about the Program or as otherwise described in this paragraph. From time to time, the Program may need to disclose certain Information to a third party who is involved in delivering Program Services. This may include, for example, a dispensing pharmacist, reimbursement navigator, field nurse service or an insurer. The Program will limit the amount of Information disclosed to only that Information required in order to deliver the Program Services to you. The Program may de-identify your information, including for use in providing data to health authorities to support drug access, for reporting purposes, publication, to conduct commercial analysis, research purposes or to improve the Program. All Information collected and recorded by the Program will be treated and maintained by Program Administrators in compliance with applicable privacy and health privacy legislation. Your Information may be collected, used and disclosed and/or stored outside of your province/territory or country, and the privacy laws of those jurisdictions may be less-stringent than the laws of Canada and/or your home province/territory. Your information will be maintained for as long as you participate in the Program and as may be required thereafter in order to meet legal and regulatory requirements. For more information or to address any additional questions, please contact the Program to speak with the privacy officer. Calls may be monitored and recorded for quality assurance or training purposes. You can withdraw your consent at any time by contacting the Program by phone at 1-84-INCYTE-00 (1-844-629-8300) or by email at support@incytesolutions.ca. If you choose to withdraw consent to the Program, please be aware that you may be ineligible for Program Services, including patient support and reimbursement assistance, from the date of withdrawal.

You understand that any financial assistance provided to you as a result of your enrolment in the Program may be reportable income to public or private payers or government agencies. You understand that you are solely responsible for such reporting as well as for ensuring compliance with accepting any such financial assistance.

If you have any questions, please feel free to contact the Program for more information in writing at 1393 North Service Rd. E., Unit 1, Oakville, ON L6H 1A7, fax 1-84-INCYTE-01 (1-844-629-8301), phone 1-84-INCYTE-00 (1-844-629-8300) or email support@incytesolutions.ca. Incyte reserves the right to change the Program Administrator on written notification to you and you consent to your information being transferred to any new Program Administrator for the purposes of continued administration of the Program. Incyte reserves the right to modify or terminate the Program at any time upon providing you with prior written notice.

Prescribing HCP Terms and Conditions

By signing this form, I acknowledge and agree that: (i) I am the prescribing HCP for this patient and am authorized to prescribe the drug product in my province of practice; (ii) this constitutes an original prescription for PEMAZYRE® (pemigatinib) for the indication specified in Section 3 of this form and, if applicable, pre-medications, (iii) Incyte may de-identify my personal information for use in providing data to health authorities to support drug access, for reporting purposes, publication, to conduct commercial analysis, research purposes or to improve the Program, (iv) I authorize the Program to send the prescription to the patient's pharmacy of choice on my behalf, (v) I have discussed the Program with the patient and have either had the patient sign the consent form, or I have obtained verbal consent from the patient to share their information with the Program for contact and enrolment purposes, as I have indicated on the first page of this form, and (vi) I understand that my information may be collected by the Program and that Incyte and/or the Program may contact me including for the purposes of administering the Program inquiring about my experience with the Program or to provide assistance relating to the prescribing of PEMAZYRE® (pemigatinib).

I understand that I may revoke this consent by contacting the Program at the contact information set out below.

Contact us to learn more about Incyte Solutions™!

1-84-INCYTE-00 (1-844-629-8300) **support@incytesolutions.ca** **1-84-INCYTE-01** (1-844-629-8301)

To report a possible adverse event or product complaint related to an Incyte product, contact Incyte Biosciences Canada Medical Information: **medinfocanada@incyte.com** or **1-833-309-2759**.

Reference: 1. PEMAZYRE® Product Monograph. Incyte Corporation. September 8, 2021.

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

Pr Pemazyre pemigatinib tablets 13.5 mg · 9 mg · 4.5 mg